View all CTOS CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recap
for Community Practice Connections™: Breakthroughs in Soft Tissue Sarcoma: Perspectives on Emerging Strategies® focuses on common clinical questions related to the management of advanced soft tissue sarcoma.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit

Community Practice Connections™: Breakthroughs in Soft Tissue Sarcoma: Perspectives on Emerging Strategies

Release Date: January 12, 2016
Expiration Date: January 12, 2017
Media: Internet - based

Activity Overview

This activity focuses on soft tissue sarcoma (STS), and features a series of short video interviews with leading experts who address a variety of questions commonly faced by practicing community oncologists. The content and interviews are based on presentations given at Breakthroughs in Soft Tissue Sarcoma: Perspectives on Emerging Strategies, a CME-certified, ancillary satellite symposium of the Annual Sarcoma Meeting held in Salt Lake City, Utah.

CME Activity Table of Contents

  • Introduction
  • Recent Advances in Frontline Therapy for Metastatic and Unresectable STS
  • Recent Advances in the Treatment of Metastatic and Unresectable STS Beyond Progression
  • Sequencing of Newer Versus Older STS Therapies
  • Emerging Options for Metastatic/Unresectable STS
  • The Importance of Collaboration Between Academic and Community Cancer Care

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and researchers interested in the treatment of STS. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with sarcoma may also participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Discuss contemporary multidisciplinary strategies utilized in the management of advanced forms of STS
  • Explain novel mechanistic approaches under investigation for the treatment of patients with metastatic or unresectable STS
  • Evaluate emerging clinical trial results in the context of evolving treatment paradigms in STS and multimodality sequencing in multiple lines of care

Faculty, Staff, and Planners' Disclosures


George D. Demetri, MD
Professor of Medicine, Harvard Medical School
Director, Ludwig Center at Harvard
Director, Center for Sarcoma and Bone Oncology
Dana-Farber Cancer Institute
Boston, MA

Robin L. Jones, BSc, MB, MRCP, MD (Res)
Consultant Oncologist
Royal Marsden Hospital
Team Leader, Sarcoma Clinical Trials
Institute of Cancer Research
London, England

William D. Tap, MD
Chief, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®

The following individuals have relevant financial relationships with commercial interests to disclose:

George D. Demetri, MD - Consultant: Bayer, Novartis, Pfizer, Lilly, EMD-Serono, Sanofi Oncology, Janssen Oncology, PharmaMar, GlaxoSmithKline, Daiichi-Sankyo, Ariad, AstraZeneca, WIRB-Copernicus Group, ZIOPHARM Oncology, Polaris; Research Support (to Dana-Farber for specific clinical trial agreements in Sarcoma Unit: Bayer, Novartis, EMD-Serono, Sanofi Oncology, Janssen Oncology, GlaxoSmithKline; Patent licensed to Novartis from Dana-Farber (royalty paid to Dana-Farber); Consultant, Scientific Advisory Board, Equity (minor stake, nonpublic): Kolltan Pharmaceuticals; Board of Directors, Scientific Advisory Board and Equity (minor stake, nonpublic): Blueprint Medicines; Consultant, Scientific Advisory Board/Equity (minor stake, nonpublic): G1 Therapeutics and Caris Life Sciences; Consultant, Scientific Advisory Board (>$10,000, <$20,000 and Equity (minor stake, nonpublic): Champions Oncology; Consultant, uncompensated, Equity (minor stake, nonpublic): Bessor Pharma; Robin L. Jones, BSc, MB, MRCP, MD (Res) - Consultant: Blueprint, Daiichi Sankyo, Adaptimmune, Immune Design, Eisai, Pharmamar, Merck, Serono, Eli Lilly, Immodulon; William D. Tap, MD - Consultant: Daiichi-Sankyo, Eli Lilly, EMD Serono, Plexxikon, Novartis; Grant/Research Support: Sarcoma Foundation of America, Threshold Pharmaceuticals; Other: Morphotek-IDMC Chair.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By